Business
LakePharma appointed for lead product development
LakePharma appointed for lead product development.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 8860U Hemogenyx Pharmaceuticals PLC 30 October 2017 \n\nHemogenyx Pharmaceuticals Plc \n(\"Hemogenyx\" or the \"Company\")\n \nLakePharma appointed as Service Provider for lead drug development\n \nHemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announced today it has chosen LakePharma, Inc. as its service provider for the development and manufacturing of Hemogenyx's lead product, CDX bi-specific antibodies. The company believes that CDX bi-specific antibodies could replace traditional methods of conditioning patients for bone marrow transplants-eliminating the need for pre-transplantation chemotherapy and radiation, which can damage a patient's health-and allow more patients to benefit from the curative power of bone marrow transplants.\n \nThe relationship between Hemogenyx Pharmaceuticals and LakePharma is designed to have a seamless product development process, from discovery to biomanufacturing, as Hemogenyx moves its cutting-edge therapies toward clinical trials. Strategically, the formalization of this relationship is particularly significant because it marks a major step in the pre-clinical development of Hemogenyx's CDX antibodies. Undertaken with the expertise and validated technology of LakePharma, the largest US-based biologics contract research organization, this step brings Hemogenyx significantly closer to its goal of taking the CDX antibodies into clinical trials at the earliest opportunity with a faster path through pre-clinical trials.\n \nDr. Vladislav Sandler, CEO of Hemogenyx, said: \"After a thorough evaluation process, we chose to partner with LakePharma for the development and manufacture of CDX antibodies for preclinical tests. The speed, quality and sophistication of LakePharma's services gives us confidence that we will go into clinical trials on time with a reliable product that will eventually save lives.\"\n \nDr. Hua Tu, Founder and CEO of LakePharma, commented: \"LakePharma has been providing antibody engineering and bioproduction service to Hemogenyx for several years and helped them to create the underlying IP for their CDX technology. We are pleased to see that LakePharma's one-stop-shop capabilit...